MENLO PARK, Calif., November 23, 2020 — SRI International has been awarded a contract of up to $107 million from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS (NIAID-DAIDS) to support basic and pre-clinical research and therapeutic product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis B and C viruses (HBV/HCV).
Under the seven-year contract issued by DAIDS, SRI Biosciences, a division of SRI International, will provide a comprehensive suite of preclinical product development services to support the formulation of potential therapeutic agents and conduct studies to assess the pharmacology and toxicology of these compounds.
These services will be used to support product discovery and development leading to Investigational New Drug Applications, Investigational Device Exemptions, and/or New Drug Application filings with the U.S. Food and Drug Administration.
“SRI has held this contract since the program began in 1991. Over the years we have assisted in the development of dozens of new drugs to treat HIV infection, secondary bacterial infections and other related infectious diseases. We are delighted that this contract will enable us to continue supporting NIAID’s Division of AIDS in this life-saving work,” said Dr. Jon Mirsalis, vice president of SRI’s Translational Development Section, and principal investigator of the program.
This project has been funded in whole or in part with Federal funds from the Division of AIDS (DAIDS), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00001.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About SRI Biosciences
SRI International, a non-profit research institute founded in 1946 and headquartered in Menlo Park, California, creates world-changing solutions to make people safer, healthier, and more productive. SRI Biosciences, a division of SRI International, integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. SRI Biosciences has advanced more than 175 drugs to clinical trials, and approximately 20 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs. SRI Biosciences collaborates with a broad range of partners from small and virtual biotechnology companies to top 10 pharmaceutical companies and other leading industry partners. More information is available at www.sri.com.
###
Media contact:
Michele Parisi
mparisi@forwardhealthinc.com
+1 925 846 5028
